Worth reading
49Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
5.9
% (year-on-year change in revenue)Wording
Conditional
How definitive the wording is.Results for this period
Full year1 April 2025 to 31 March 2026ConsolidatedJapanese GAAPNet Sales718,163¥ millionYear on year +5.9%Progress 97.0%
Operating profit24,482¥ millionYear on year -1.2%Progress 94.2%
Ordinary income26,331¥ millionYear on year +1.2%Progress 99.4%
Net income attributable to owners of the parent13,394¥ millionYear on year -11.5%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥144.19
Operating Margin3.4%
Financial position at period-end
Total assets385,109¥ million
of which net assets 152,428 ¥ millionEquity ratio 39.2%vs. prior year-end +0.1pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+22,078
Investment-2,075
Financials-16,334
Net change+3,669
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥78,604 million
Segment revenueTotal Pack Produce Business ¥136,604 million (YoY +2.6%), Medical Supply Business ¥509,569 million (YoY +7.3%), Life Care Business ¥37,322 million (YoY +1.8%), Dispensing Pharmacy Business ¥34,666 million (YoY +3.6%)
Segment profitTotal Pack Produce Business ¥10,812 million (YoY -10.0%), Medical Supply Business ¥7,484 million (YoY +7.4%), Life Care Business ¥2,216 million (YoY +1.2%), Dispensing Pharmacy Business ¥4,004 million (YoY +16.9%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥740,000 million (YoY +3.0%)
Operating profit¥26,000 million (YoY +6.2%)
Ordinary income¥26,500 million (YoY +0.6%)
Profit attributable to owners of the parent¥16,000 million (YoY +19.5%)
Annual Dividend Forecast¥58 → ¥65（+12.1%）
Payout ratio41.6
Factors Behind Changes in Business Performance
Contributions from the ODA specialist trading business, steady performance in the medical information solutions business, the launch of new SPD contracts for facilities and bundled SPD contracts with multiple hospitals, and growth in the number of contracted facilities contributed to higher sales and profits. Factors reducing profit included the absence of senior-oriented condominium projects completed during the fiscal year, delays in the delivery of materials, higher component prices and production delays, M&A fees, and higher utility and labor costs in the nursing care services business.
Disclosure regarding the going concern assumption
Not applicable.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 5 / Company name ㈱テックインターナショナル, デルフィア㈱, ㈱橋本薬局, マスターズフォレスト㈱, 昭島国際法務マネジメント㈱ / Excluded Number of companies 11 / Company name シップヘルスケアエステート東日本㈱, インジニアス㈱, キングラン・メディケア㈱, キングラン九州㈱, キングラン北海道㈱, キングラン関西㈱, 日星調剤㈱, グリーンファーマシー㈱, ㈲スターシップ, ㈱ＭＯＮＡＫＡ, ㈱オーエムピー, グラン・グルメ㈱
Material subsequent eventsNot applicable.
Impairment loss¥0 million
Breakdown of extraordinary income (loss)Extraordinary income Item Gain on sale of non-current assets / Amount ¥16 million, Item Gain on sale of investment securities / Amount ¥49 million, Item Gain on sale of shares in an affiliated company / Amount ¥36 million, Item Other / Amount ¥5 million / Extraordinary loss Item Loss on sale of fixed assets / Amount ¥6 million, Item Loss on Disposal of Fixed Assets / Amount ¥158 million, Item Impairment Loss on Investment Securities / Amount ¥738 million, Item Provision for allowance for doubtful accounts / Amount ¥2,415 million, Item Other / Amount ¥14 million
Depreciation and amortization¥5,476 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingAvailable (for institutional investors and analysts)
Issued Shares at Period-End94,350,134
Treasury Shares at Period-End2,331,200
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025 to 31 March 2026 |
| Net Sales | ¥718,163 million (YoY +5.9%) |
| Operating profit | ¥24,482 million (YoY -1.2%) |
| Ordinary income | ¥26,331 million (YoY +1.2%) |
| Profit attributable to owners of the parent | ¥13,394 million (YoY -11.5%) |
| Net income per share | ¥144.19 |
| Operating Margin | 3.4% |
| Equity ratio | End of the current fiscal period 39.2 / End of previous period 39.1 |
| Total assets | ¥385,109 million |
| Net assets | ¥152,428 million |
| Cash flows from operating activities | ¥22,078 million |
| Cash flows from investing activities | ¥-2,075 million |
| Cash flows from financing activities | ¥-16,334 million |
| Cash and cash equivalents at end of period | ¥78,604 million |
| Full-year earnings forecast | Net Sales ¥740,000 million (YoY +3.0%) / Operating profit ¥26,000 million (YoY +6.2%) / Ordinary income ¥26,500 million (YoY +0.6%) / Profit attributable to owners of the parent ¥16,000 million (YoY +19.5%) |
| Annual Dividend Forecast | ¥58 → ¥65（+12.1%） |
| Payout ratio | 41.6 |
| Segment revenue | Total Pack Produce Business ¥136,604 million (YoY +2.6%), Medical Supply Business ¥509,569 million (YoY +7.3%), Life Care Business ¥37,322 million (YoY +1.8%), Dispensing Pharmacy Business ¥34,666 million (YoY +3.6%) |
| Segment profit | Total Pack Produce Business ¥10,812 million (YoY -10.0%), Medical Supply Business ¥7,484 million (YoY +7.4%), Life Care Business ¥2,216 million (YoY +1.2%), Dispensing Pharmacy Business ¥4,004 million (YoY +16.9%) |
| Depreciation and amortization | ¥5,476 million |
| Impairment loss | ¥0 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Item Gain on sale of non-current assets / Amount ¥16 million, Item Gain on sale of investment securities / Amount ¥49 million, Item Gain on sale of shares in an affiliated company / Amount ¥36 million, Item Other / Amount ¥5 million / Extraordinary loss Item Loss on sale of fixed assets / Amount ¥6 million, Item Loss on Disposal of Fixed Assets / Amount ¥158 million, Item Impairment Loss on Investment Securities / Amount ¥738 million, Item Provision for allowance for doubtful accounts / Amount ¥2,415 million, Item Other / Amount ¥14 million |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 5 / Company name ㈱テックインターナショナル, デルフィア㈱, ㈱橋本薬局, マスターズフォレスト㈱, 昭島国際法務マネジメント㈱ / Excluded Number of companies 11 / Company name シップヘルスケアエステート東日本㈱, インジニアス㈱, キングラン・メディケア㈱, キングラン九州㈱, キングラン北海道㈱, キングラン関西㈱, 日星調剤㈱, グリーンファーマシー㈱, ㈲スターシップ, ㈱ＭＯＮＡＫＡ, ㈱オーエムピー, グラン・グルメ㈱ |
| Material subsequent events | Not applicable. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 94,350,134 |
| Treasury Shares at Period-End | 2,331,200 |
| Factors Behind Changes in Business Performance | Contributions from the ODA specialist trading business, steady performance in the medical information solutions business, the launch of new SPD contracts for facilities and bundled SPD contracts with multiple hospitals, and growth in the number of contracted facilities contributed to higher sales and profits. Factors reducing profit included the absence of senior-oriented condominium projects completed during the fiscal year, delays in the delivery of materials, higher component prices and production delays, M&A fees, and higher utility and labor costs in the nursing care services business. |
Items this document does not state (4)
Revision to Earnings ForecastShareholder Return PolicyRegional salesOrders received and order backlog
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Sales growth was driven by contributions from the ODA specialist trading business, steady performance in medical information solutions, and the launch of new SPD contracts for facilities and bundled SPD contracts with multiple hospitals. Profit was adversely affected by the absence of senior-oriented condominium projects completed during the fiscal year, delays in the delivery of materials, higher component prices and production delays, and M&A fees.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.